

Fiscal Year 2009 Annual Review of Ocular Allergy Products

Oklahoma Health Care Authority
April 2010

Current Prior Authorization of Ocular Allergy Products

The Ocular Allergy PBPA category was initially implemented in July of 2007. The following are the current tier chart and approval criteria.

Tier 2 Authorization Criteria

1. FDA approved diagnosis
2. A trial of at least one Tier 1 product of a similar type for a minimum of two weeks in the last 30 days (i.e., cromolyn sodium prior to use of a mast cell stabilizer product or OTC Zaditor® prior to use of a tier two in the same category)
3. Documentation of clinical need for Tier 2 product over Tier 1 should be noted on the petition
4. Clinical exceptions granted for products with allergic reaction or contraindication

Tier-1	Tier-2
cromolyn sodium (Crolom®)	nedocromil sodium (Alocril®)
ketotifen fumarate (Alaway™)	pemirolast potassium (Alamast®)
ketotifen fumarate (Zaditor® OTC)	emedastine difumarate (Emadine®)
olopatadine (Patanol®)	loteprednol etabonate (Alrex®)
	olopatadine (Pataday™)
	lodoxamide tromethamine (Alomide®)
	epinastine (Elestat®)
	azelastine (Optivar®)

Mandatory generic plan applies


Current tiers based on Supplemental Rebate participation

Utilization of Ocular Allergy Products


Comparison of Fiscal Year Utilization

Fiscal Year	Members	Claims	Paid	Paid/Claim	Perdiem	Units	Days
2008	4,858	7,475	\$626,628.83	\$83.83	\$2.94	34,214	213,188
2009	5,291	7,725	\$664,173.03	\$85.98	\$3.14	35,929	211,363
% Change	8.90%	3.30%	6.00%	2.60%	6.80%	5.00%	-0.90%
Change	433	250	\$37,544.20	\$2.15	\$0.20	1,715	-1,825

Demographics of Members Utilizing Ocular Allergy Products: FY 2009




Top Prescribers of Ocular Allergy Products by Number of Claims: FY 2009



Prior Authorization of Ocular Allergy Products

There were a total of 412 petitions submitted for this PBPA category during fiscal year 2009. The following shows the status of the submitted petitions.

Status of Petitions for Ocular Allergy Products: FY 2009



Conclusion and Recommendations

The College of Pharmacy recommends no changes to this category at this time.

Chemical Name	Brand Name	Claims	Members	Amount Paid	Claims/Member	Per diem	% Paid
Olopatadine	PATANOL SOL 0.1% OP	4,650	3,400	\$417,514.28	1.37	\$3.16	62.86%
Olopatadine	PATADAY SOL 0.2%	1,725	1,198	\$150,387.89	1.44	\$3.59	22.64%
Azelastine	OPTIVAR DRO 0.05%	523	417	\$48,748.03	1.25	\$3.09	7.34%
Epinastine	ELESTAT DRO 0.05%	277	219	\$25,265.81	1.26	\$3.17	3.80%
Loteprednol	LOTEMAX SUS 0.5%	161	119	\$11,680.49	1.35	\$3.35	1.76%
Cromolyn	CROMOLYN SOD SOL 4% OP	103	60	\$1,118.03	1.72	\$0.38	0.17%
Ketotifen	KETOTIFEN DRO FUMARATE	77	62	\$1,106.17	1.24	\$0.60	0.17%
Ketotifen	ZADITOR DRO 0.025%OP	77	56	\$1,087.31	1.38	\$0.52	0.16%
Loteprednol	ALREX SUS 0.2%	73	25	\$4,932.32	2.92	\$2.46	0.74%
Ketotifen	ALAWAY DRO 0.025%OP	32	30	\$341.12	1.07	\$0.38	0.05%
Nedocromil	ALOCRI SOL 2%	15	5	\$1,289.50	3	\$5.16	0.19%
Ketotifen	ZADITOR SOL 0.025%OP	10	8	\$675.80	1.25	\$2.90	0.10%
Ketotifen	REFRESH EYE DRO ITCH REL	1	1	\$14.25	1	\$0.48	0.00%
Ketotifen	EYE ITCH REL DRO 0.025%OP	1	1	\$12.03	1	\$0.40	0.00%
Totals		7,725	5,291*	\$664,173.03	1.46	\$3.14	100.00%

*Total Number of Unduplicated Members